STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 3 / Line 44	Methods in Abtract/
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3/ Lines 48-56	Results in Abstract/
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Pages 5-6 /Lines 65-89	Introduction Section/ Paragraphs 1-2 in Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 6 / Lines 85-89	Introduction Section/
Methods				
Study design	4	Present key elements of study design early in the paper	Page 6 /Line 93	Study design and
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6 / Lines 93-94; 104-105	Study design and participants Section/Paragraphs 1-3 in
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Cross-sectional study Page 6/ Lines 97-109	Study design and participants Section/ Paragraphs 2-3 in Methods Section
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	Cross-sectional study	Cross-sectional study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pages 6-7/Lines 104-109	Study design and participants Section /Paragraph 3 in
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pages 7-8 / Lines 111-141	Echocardiography and ultrasound measurements Section / Paragraphs 4-5 in
Bias	9	Describe any efforts to address potential sources of bias	Page 7 / Lines 116-118	Echocardiography and
Study size	10	Explain how the study size was arrived at	Pages 8-9 / Lines 151-154	Statistical analysis
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pages 6-9 / Lines 104-109; 149-154	Study design and Statistical analysis Section / Paragraphs 3 and

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Pages 8-9 / Lines 142-154	Statistical analysis
		(b) Describe any methods used to examine subgroups and interactions	Page 8 / Lines 148-151	Statistical analysis
		(c) Explain how missing data were addressed	Page 8 / Lines 151-152	Statistical analysis
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	Page 6 / Lines 93-94	Study design and participants Section / Paragraph 1 in Methods Section
		(e) Describe any sensitivity analyses	This part was not	This part was not
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 9 / Lines 156-166	Results Section / Paragraph 1 in Results Section
		(b) Give reasons for non-participation at each stage	Page 9 / Lines 156-159	esults Section / Paragraph
		(c) Consider use of a flow diagram	We have described them	We have described them
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 9 / Lines 161-168	Results Section / Paragraph 1 in Results Section
		(b) Indicate number of participants with missing data for each variable of interest	Page 9 / Lines 156-161	Results Section /
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	N/A	N/A
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	N/A	N/A
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		Cross-sectional study—Report numbers of outcome events or summary measures	Pages 9-11 /Lines 156-200	Results
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 9/ Lines 169-172	Results Section / Paragrph 2 in Results Section
		(b) Report category boundaries when continuous variables were categorized	Pages 10-11 /Lines	Results Section /
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Evaluation of risk ratio	Evaluation of risk ratio
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Pages 10-11/Lines 173-200	Results
Discussion				
Key results	18	Summarise key results with reference to study objectives	Pages 11-13 /Lines	Discussion Section /
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pages 13-14 / Lines 260-264	Discussion Section / Paragraph 4 in Discussion Section

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pages 13-14 / Lines 260-264	Discussion Section / Paragraph 4 in Discussion Section
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 14 / Lines 265-270	Discussion Section / [illegible]
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 1 /Lines 20-21	Title page

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/qims-21-644.
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.